The Research Progress of Proteomics Used in Parkinson’s Disease

Abstract

Abstract: Parkinson’s disease （PD） is an age-related，neurodegenerative disease characterized by progressive degeneration of dopaminergic neurons in the substantia nigra. The etiology and pathogenesis are still unknown. Proteomics is used to study the expressions of the proteins in the overall level in different states of disease or under the external factor. It offers the powerful basis for the pathogenesis of PD，discovering the markers for diagnosis of PD searching
new spot and reliable drugs. In this paper，we review the progress in application of proteomics in PD animal and cell models，pathogenesis，diagnosis and drug treatment of PD.

Key words: proteomics, Parkinson&, rsquo, s disease, neurodegenerative disease

CLC Number:

R742.5

HAO Jun-rong，SHEN Li-xia. The Research Progress of Proteomics Used in Parkinson’s Disease[J]. Acta Neuropharmacologica, 2015, 5(3): 28-35.

References

[ ] 刘韬. 蛋白酶体抑制剂诱导的帕金森病细胞模型早期的蛋白质组学研究[D].长春：吉林大学博士学位论文, 2010.

[ ] Storch A, Kaftan A, Burkhardt K, et al. 6-Hydroxydopamine toxicity towards human SH-SY5Y dopaminergic neuroblastoma cells: independent of mitochondrial energy metabolism[J].J Neural Transm, 2000, 107(3): 281-293.

[ ] Singh M P, Patel S, Dikshit M, et al.Contribution of genomics and proteomics in understanding the role of modifying factors in Parkinson's disease[J].Indian J Biochem Biophys, 2006, 43(2): 69-81.

[ ] Hon-Chung Fung, Chiung-Mei Chen, John Hardyb, et al. Analysis of the PINK 1 gene in a cohort of patients with sporadic early-onset parkinsonism in Taiwan[J]．Neurosci Lett, 2006;394(1): 33-36.

[ ] C. Alves da Costa. Recent advances on alpha-synuclein cell biology: functions and dysfunctions Parkinson’s disease[J]. Curr Mol Med, 2003, 3(1): 17-24.

[ ] Deborah E Cabin, Kazuhiro Shimazu, Diane Murphy, et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein[J].J Neurosci, 2002, 22(20): 8797-8807.

[ ] Magali Periquet, Olga Corti, Sandrine Jacquier, et al. Proteomic analysis of parkin knockout mice: alterations in energy metabolism, protein handling and synaptic funetion[J].J Neurochem, 2005, 95(5): 1259-1276.

[ ] Madeleine Diedrich, Lei Mao, Christian Bernreuther, et al. Proteome analysis of ventral midbrain in MPTP-treated normal and L1cam transgenic mice[J].Proteomics, 2008, 8(6): 1266-1275.

[ ] Klein Christine, Lohmann-Hedrich Katja. Impact of recent genetic findings in Parkinson’s disease[J]. Current Opinion Neurology, 2007, 20(4): 453-464.

[ ] 张艳梅, 常明, 邹伟, 等. MPP+诱导PC12细胞损伤的蛋白质组学研究[J].中风与神经疾病杂志, 2007, 24(5): 537-540.

[ ] Joungil Choi, Allan I Levey, Susan T Weintraub, et al. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases[J]. J biol Chem, 2004, 279(13): 13256-13264.

[ ] 张颖, 杨艺敏, 白晶, 等. PSI诱导PC12细胞的PD模型中分子伴侣家族的氧化修饰[J].中风与神经疾病杂志, 2010, 27(6): 503-507.

[ ] 王丹萍, 常明, 解洪荣, 等. 6-羟基多巴胺诱导SH-SY5Y细胞帕金森病模型中Peroxiredoxin6表达的研究[J].中风与神经疾病杂志, 2009, 26(6): 668-671.

[ ] 周长青, 杨旭, 杨云鹏, 等. 鱼藤酮和MPTP慢性帕金森病小鼠黑质共同差异蛋白研究[J].第三军医大学学报, 2011, 33(14): 1432-1436.

[ ] 刘韬, 金英花, 张瑜, 等.蛋白酶体抑制剂诱导的PC12细胞帕金森病模型中血红素加氧酶-1的差异表达[J].中国生物制品学杂志, 2010, 23(8): 816-821.

[ ] 田明秀, 常明, 朱本清, 等. 多巴胺诱导SH-SY5Y细胞帕金森病模型中GRP78的表达[J]. 吉林大学学报: 医学版, 2010, 36(1): 76-82.

[ ] 张磊, 张思瑾, 常明, 等.蛋白酶体抑制剂诱导的帕金森病模型中galectin-1含量变化的研究[J].脑与神经疾病杂志, 2010, 18(2): 101-105.

[ ]Xie Hong-rong , Chang Ming , Hu Xin-yu , et al. Proteomics analysis of MPP+-induced apoptosis in SH-SY5Y cells[J].Neurological Sciences, 2011, 32(2): 221-228.

[ ] Magali Periquet, Olga Corti, Sandrine Jacquier, et al. Proteomic analysis of Parkin knockout mice: alterations in energy metabolism, protein handling and synaptic funetion[J]. J Neurochemistry, 2005, 95(5): 1259-1276.

[ ] Karl Sköld, Marcus Svensson, Anna Nilsson, et al. Decreased striatal levels of PEP-19 following MPTP lesion in the mouse[J]. J Biological Chemistry, 2006, 5(2): 262-269.

[ ] John A Putkey, Quinn Kleerekoper, Tara R Gaertner, et al. A new role for IQ motif proteins in regulating calmodulin function[J]. J Biological Chemistry, 2003, 278(50): 49667-49670.

[ ]Xiong Yan, Zhang Yong-qian, Javed Iqbal, et al. Differential expression of synaptic proteins in unilateral 6-OHDA lesioned rat model-A comparative proteomics approach[J].Proteomics, 2014, 14(15): 1808-1819.

[ ]Jin Jing-hua, Gloria E Meredith, Leo Chen, et al. Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewybody formation and Parkinson’s disease[J].Molecular Brain Research, 2005, 134(1): 119-138.

[ ] Ted M Dawson, Valina L Dawson. Molecular pathways of neurodegeneration in parkinson’s disease[J]. Seience, 2003, 302(5646): 819-822.

[ ] Angela De Iuliis, Jessica Grigoletto, Alessandra Recchia, et al. A proteomic approach in the study of animal model of Parkinson's disease[J].Clinica Chimica Acta, 2005, 357(2): 202-209.

[ ] Xin Zhao, Quan Li, Lei Zhao, et al Proteome analysis of substantia nigra and striatal tissue in the mouse MPTP model of Parkinson's disease[J].Proteomics Clin Appl, 2007, 1(12): 1559-1569.

[ ] M Basso, S Giraudo, L Lopiano, et al. Proteome analysis of mesencephalic tissues: evidence for parkinson's disease[J].Neurological Sciences, 2003, 24(3): 155-156.

[ ] Virginie Licker, Natacha Turck, Enikö Kövari, et al. Proteomic analysis of human substantia nigra identifies novel candidates involved in Parkinson's disease pathogenesis[J].Proteomics, 2014, 14(6): 784-794.

[ ] Cornelius J Werner, Roland Heyny-von Haussen, Gerhard Mall, et al. Proteome analysis of human substantia nigra in Parkinson's disease[J].Proteome Science, 2008, 6: 8.

[ ] Omar M A El-Agnaf, Sultan A Salem, Katerina E Paleologou, et al. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fiuids, including human plasma[J].J FASEB, 2003, 17(13): 1945-1947.

[ ] Masaaki Waragai, Jianshe Wei, Masayo Fujita, et al. Inereased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease[J].Biochemical and Biophysical Research Communications, 2006, 345(3): 967-972.

[ ]Liu Ying-jun, Zhou Qin-bo, Tang Mi, et al. Upregulation of alphaB-crystallin expression in the substantia nigra of patients with Parkinson's disease[J].Neurobiol Aging, 2015, Jan 22.

[ ] Singh M P, Patel S, Dikshit M, et al. Contribution of genomics and proteomics in understanding the role of modifying factors in Parkinson's disease[J].Indian J Biochem Biophys, 2006, 43(2): 69-81.

[ ] John E Hale, Valentina Gelfanova, Jin-Sam You, et al. Proteomics of cerebrospinal fluid: methods for sample proeessing[J].Methods Mol Biol, 2008, 425: 53-66.

[ ] Karin D van Dijk, Charlotte E Teunissen, Benjamin Drukarch, et al. Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach[J].Neurobiol Disease, 2010, 39(3): 229-241.

[ ]王晓晖, 杨威, 祁金顺. 胰高血糖素样肽1阿尔茨海默病治疗新策略[J].生理学报, Acta Physiologica Sinica, 2010, 62(5): 398-406.

[ ] 龙汉春, 徐珊, 万金城, 等. GLP-1蛋白可能是帕金森病诊治密切相关的靶点[J].中国医学工程, 2014, 22(5): 25-27.

[ ] Lance M Villeneuve, Phillip R Purnell, Michael D Boska, et al. Early expression of Parkinson's disease-related mitochondrial abnormalities in PINK1 knockout rats[J].Molecular Neurobiology, 2014, 53(1): 171-186.

[ ] Jing Zhang, Izabela Sokal, Elaine R. Peskind, et al. CSF multianalyte Profile distinguishes Alzheimer and Parkinson diseases[J]. American J Clinical Pathology, 2008, 129(4): 526-529.

[ ]Li Xu-zhao, Zhang Shuai-nan, Wang Ke-xin, et al. iTRAQ-based quantitative proteomics study on the neuroprotective effects of extract of Acanthopanax senticosus harm on SH-SY5Y cells overexpressing A53T mutant α-synuclein[J].Neurochemistry International, 2014, 72: 37-47.

[ ]Silvia Mila, Alessandra Giuliano Albo, Davide Corpillo, et al. Lymphocyte proteomics of Parkinson's disease patients reveals cytoskeletal protein dysregulation and oxidative stress[J].Biomarkers in Medicine.2009, 3(2): 117-128.

[1]	LI Hui, YANG Jin-shui, XUE Qian. A Case of Huntington's Disease with Involuntary Movements of the Limbs as the First Symptom Combined with Dysarthria in the Early Stages of the Disease [J]. ACTA NEUROPHARMACOLOGICA, 2024, 14(6): 31-.
[2]	ZHANG Yuan-qing, LIN Yu, HUANG Li. Study on the Effects of Vitamin D on DNA Methylation in Alzheimer's Disease Cell Models [J]. ACTA NEUROPHARMACOLOGICA, 2024, 14(6): 39-.
[3]	ZHAO Yu-ting, YIN Hong-yan, GUO Chun-yan. Explore the Mechanism of Paeoniae Radix Alba Delaying Alzheimer's Disease Based on Network Pharmacology and Molecular Docking [J]. ACTA NEUROPHARMACOLOGICA, 2024, 14(5): 1-.
[4]	ZHANG Xin, YAO Si-fan, MA Meng-fan, SHEN Li-xia. Recent Progress in the Metabolomics of Alzheimer's Disease [J]. ACTA NEUROPHARMACOLOGICA, 2024, 14(5): 47-.
[5]	YAO Si-fan, ZHANG Xin, SHEN Li-xia. Effects of Tau Protein on Mitochondrial Function in Alzheimer's Disease [J]. ACTA NEUROPHARMACOLOGICA, 2024, 14(4): 54-.
[6]	WANG Tian-xu, LIU Ci, CUI Yong-yuan, ZHANG Xin, WU Miao-miao, SHEN Li-xia. Explore the Mechanism of Quercetin in the Treatment of Alzheimer's Disease by Network Pharmacology and Molecular Docking [J]. ACTA NEUROPHARMACOLOGICA, 2024, 14(2): 31-.
[7]	YIN Hong-yan, YOU Si-han, GUO Chun-yan. Research Progress of Core Markers and Other Markers of Alzheimer's Disease [J]. ACTA NEUROPHARMACOLOGICA, 2023, 13(6): 45-.
[8]	ZHU Jing-yi , FAN Jian-chun, YU Ai-mei. Research Status on the Neuroprotective Effect of Probucol [J]. ACTA NEUROPHARMACOLOGICA, 2023, 13(6): 50-.
[9]	. Exploring the Effect and Mechanism of Pterostilbene on Alzheimer’s Disease Based on Network Pharmacology [J]. ACTA NEUROPHARMACOLOGICA, 2023, 13(5): 1-.
[10]	BAI Jing-ru, YOU Si-han, YIN Hong-yan, YANG Song-rui, GUO Chun-yan. Predicting the Target of Peach Kernel in the Treatment of Parkinson's Disease Based on Network Pharmacology [J]. ACTA NEUROPHARMACOLOGICA, 2023, 13(3): 31-.
[11]	YU Mei-hua, ZHOU Jing, GAO Shi-jie, BAO Jin-feng. Mechanism of Sirtuins in Neurodegenerative Diseases [J]. ACTA NEUROPHARMACOLOGICA, 2023, 13(1): 35-.
[12]	GUO Bao, LIU Zi-ming, JING Yong-shuai, ZHANG Dan-shen. Correlation Between Wnt Signaling Pathway and Alzheimer's Disease and Its Targets [J]. ACTA NEUROPHARMACOLOGICA, 2023, 13(1): 56-.
[13]	SI Wen-ying, HOU Yu-qing, SUN Xiao-jing, MENG Xian-yong, DONG Xiao-hua. Gene Therapy for Alzheimer’s Disease [J]. ACTA NEUROPHARMACOLOGICA, 2022, 12(6): 51-56.
[14]	ZHANG Zhi-qing, ZHANG Yong-cai, LIU Lin-xuan, LI Ren-qing, LIU Ji-jia, DU Jing-kao, JIANG Bei, WEI Huiping, SU Li-ning. Bioinformatics Analysis of the Relationship between Exosomal ceRNA Regulatory Network and Alzheimer’s Disease [J]. ACTA NEUROPHARMACOLOGICA, 2022, 12(4): 23-40.
[15]	CAI Yu-shan, ZHAO Shuai. Role of PPARβ/δ in Neurodegenerative Diseases [J]. ACTA NEUROPHARMACOLOGICA, 2022, 12(4): 41-48.